i
Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel
-
4 2023
-
-
Source: Emerg Infect Dis. 2023; 29(4):771-777
[PDF-1.07 MB]
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Description:We assessed effectiveness of the BNT162b2 vaccine against infection with the B.1.1.529 (Omicron) variant (mostly BA.1 subvariant), among children 5-11 years of age in Israel. Using a matched case-control design, we matched SARS-CoV-2-positive children (cases) and SARS-CoV-2-negative children (controls) by age, sex, population group, socioeconomic status, and epidemiologic week. Vaccine effectiveness estimates after the second vaccine dose were 58.1% for days 8-14, 53.9% for days 15-21, 46.7% for days 22-28, 44.8% for days 29-35, and 39.5% for days 36-42. Sensitivity analyses by age group and period demonstrated similar results. Vaccine effectiveness against Omicron infection among children 5-11 years of age was lower than vaccine efficacy and vaccine effectiveness against non-Omicron variants, and effectiveness declined early and rapidly.
-
Subjects:
-
Source:
-
Pubmed ID:36863005
-
Pubmed Central ID:PMC10045694
-
Document Type:
-
Place as Subject:
-
Volume:29
-
Issue:4
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
